PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
CRH plc (CRH)
114.271.68 (1.49%)
111.48 - 114.40
76.75 - 114.40
5.09M / 4.23M (Avg.)
23.96 | 4.77
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
69.54%
Revenue growth above 1.5x PUK's 27.93%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
483.23%
Gross profit growth above 1.5x PUK's 27.93%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
2778.72%
EBIT growth above 1.5x PUK's 246.79%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
2778.72%
Operating income growth above 1.5x PUK's 27.93%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
307.97%
Net income growth under 50% of PUK's 2157.71%. Michael Burry would suspect the firm is falling well behind a key competitor.
283.33%
EPS growth under 50% of PUK's 1749.71%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
275.00%
Diluted EPS growth under 50% of PUK's 1749.71%. Michael Burry would worry about an eroding competitive position or excessive dilution.
22.77%
Slight or no buybacks while PUK is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
23.91%
Slight or no buyback while PUK is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
243.99%
Positive 10Y revenue/share CAGR while PUK is negative. John Neff might see a distinct advantage in product or market expansion over the competitor.
100.73%
Positive 5Y CAGR while PUK is negative. John Neff might see an underappreciated edge for the firm vs. the competitor.
64.96%
Positive 3Y CAGR while PUK is negative. John Neff might view this as a sharp short-term edge or successful pivot strategy.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
469.00%
Net income/share CAGR above 1.5x PUK's 202.69% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
106.91%
Below 50% of PUK's 835.13%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
97.91%
3Y net income/share CAGR above 1.5x PUK's 48.42%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
We cut SG&A while PUK invests at 0.00%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.